Philip L Hazell

Summary

Affiliation: New South Wales
Country: Australia

Publications

  1. ncbi Acute treatment of mania in children and adolescents
    Philip Hazell
    Discipline of Psychiatry, Sydney Medical School, University of New South Wales, Thomas Walker Hospital, Sydney, NSW, Australia
    Curr Opin Psychiatry 25:264-70. 2012
  2. ncbi Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder
    Philip Hazell
    University of Sydney and University of Newcastle, NSW, Australia
    Australas Psychiatry 18:556-9. 2010
  3. ncbi Group therapy for repeated deliberate self-harm in adolescents: failure of replication of a randomized trial
    Philip L Hazell
    Thomas Walker Hospital Rivendell, Hospital Rd Concord West, NSW 2138, Australia
    J Am Acad Child Adolesc Psychiatry 48:662-70. 2009
  4. ncbi Editorial review: Shifting views on juvenile bipolar disorder and pervasive developmental disorder
    Philip Hazell
    Discipline of Psychological Medicine, University of Sydney, Australia
    Curr Opin Psychiatry 21:328-31. 2008
  5. ncbi Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder
    Philip Hazell
    Discipline of Psychiatry, School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia
    J Paediatr Child Health 43:19-24. 2007
  6. ncbi Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations
    Philip Hazell
    Thomas Walker Hospital Rivendell Child, Adolescent and Family Mental Health Service, Concord West, New South Wales, Australia
    CNS Drugs 21:37-46. 2007
  7. ncbi Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis
    Philip L Hazell
    Discipline of Psychological Medicine, Concord Clinical School, The University of Sydney, Australia
    J Atten Disord 15:674-83. 2011
  8. ncbi How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis
    Gregory W van Wyk
    Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia
    J Atten Disord 16:314-24. 2012
  9. ncbi A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children
    Philip L Hazell
    University of Newcastle, New South Wales, Australia
    J Am Acad Child Adolesc Psychiatry 42:886-94. 2003
  10. ncbi Self-injury in Australia: a community survey
    Graham Martin
    Discipline of Psychiatry, University of Queensland, Brisbane, QLD, Australia
    Med J Aust 193:506-10. 2010

Detail Information

Publications21

  1. ncbi Acute treatment of mania in children and adolescents
    Philip Hazell
    Discipline of Psychiatry, Sydney Medical School, University of New South Wales, Thomas Walker Hospital, Sydney, NSW, Australia
    Curr Opin Psychiatry 25:264-70. 2012
    ..To examine critically data concerning the efficacy and safety of acute treatments for mania in children and adolescents, in the light of considerable recent emergent evidence...
  2. ncbi Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder
    Philip Hazell
    University of Sydney and University of Newcastle, NSW, Australia
    Australas Psychiatry 18:556-9. 2010
    ..Moderate to severe cases usually require a combination of pharmacotherapy, which may include clonidine, and behaviour management. Severe or refractory cases may require the introduction of an atypical antipsychotic such as risperidone...
  3. ncbi Group therapy for repeated deliberate self-harm in adolescents: failure of replication of a randomized trial
    Philip L Hazell
    Thomas Walker Hospital Rivendell, Hospital Rd Concord West, NSW 2138, Australia
    J Am Acad Child Adolesc Psychiatry 48:662-70. 2009
    ..To replicate a study, which found group therapy superior to routine care in preventing the recurrence of self-harming behavior in adolescents who had deliberately harmed themselves on at least two occasions...
  4. ncbi Editorial review: Shifting views on juvenile bipolar disorder and pervasive developmental disorder
    Philip Hazell
    Discipline of Psychological Medicine, University of Sydney, Australia
    Curr Opin Psychiatry 21:328-31. 2008
    ..To examine the changes in prevalence estimates and concepts of core disorder in two child mental disorders that were once considered rare, and to place these changes in a cultural context...
  5. ncbi Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder
    Philip Hazell
    Discipline of Psychiatry, School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia
    J Paediatr Child Health 43:19-24. 2007
    ..Moderate benefit is derived from methylphenidate, atomoxetine, some anticonvulsant medications, guanfacine and donepezil. Data show dexamphetamine, clonidine, clomipramine, mirtazapine, and fluoxetine are of unlikely benefit...
  6. ncbi Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations
    Philip Hazell
    Thomas Walker Hospital Rivendell Child, Adolescent and Family Mental Health Service, Concord West, New South Wales, Australia
    CNS Drugs 21:37-46. 2007
    ..A negotiated trial of time off treatment followed by a review of the patient's symptoms can avert premature discontinuation of treatment...
  7. ncbi Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis
    Philip L Hazell
    Discipline of Psychological Medicine, Concord Clinical School, The University of Sydney, Australia
    J Atten Disord 15:674-83. 2011
    ..This noninferiority meta-analysis compared core ADHD symptom response between atomoxetine and methylphenidate in children and adolescents...
  8. ncbi How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis
    Gregory W van Wyk
    Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia
    J Atten Disord 16:314-24. 2012
    ..To assess how threshold oppositional defiant disorder (ODD), inattention, and hyperactivity-impulsivity affect the response to atomoxetine versus methylphenidate...
  9. ncbi A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children
    Philip L Hazell
    University of Newcastle, New South Wales, Australia
    J Am Acad Child Adolesc Psychiatry 42:886-94. 2003
    ..To compare clonidine with placebo added to ongoing psychostimulant therapy for the treatment of attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder or conduct disorder...
  10. ncbi Self-injury in Australia: a community survey
    Graham Martin
    Discipline of Psychiatry, University of Queensland, Brisbane, QLD, Australia
    Med J Aust 193:506-10. 2010
    ..To understand self-injury and its correlates in the Australian population...
  11. ncbi Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?
    Philip Hazell
    University of Newcastle and Hunter New England Mental Health Service, Australia
    Expert Opin Pharmacother 6:1989-98. 2005
    ..Although adrenergically active drugs may be the preferred treatment in the presence of severe comorbidity, for the most part they remain second-line treatment for ADHD...
  12. ncbi Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder
    Philip Hazell
    Child and Youth Mental Health Service, University of Newcastle, Locked Bag 1014, Wallsend, NSW 2287, Australia
    Eur Child Adolesc Psychiatry 15:105-10. 2006
    ..To examine the influence of comorbid oppositional defiant disorder (ODD) on the relative risk (RR) of relapse during 9 months of treatment with atomoxetine for attention-deficit/hyperactivity disorder (ADHD)...
  13. ncbi Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder
    Philip Hazell
    University of Newcastle and Wallsend Hospital, Child and Youth Mental Health Service, Newcastle, NSW, Australia
    Australas Psychiatry 12:369-75. 2004
    ....
  14. ncbi A symposium on Attention Deficit Hyperactivity Disorder (ADHD). 'Kid in the corner'
    Philip Hazell
    Child and Adolescent Psychiatry, University of Newcastle, Callaginan, 2308, New South Wales, Australia
    Aust N Z J Psychiatry 36:475-7. 2002
  15. ncbi Long-chain omega-3 polyunsaturated fatty acids in the blood of children and adolescents with juvenile bipolar disorder
    Edward H Clayton
    NSW Department of Primary Industries, Wagga Wagga Agricultural Institute, Pine Gully Rd, Wagga Wagga, NSW, 2650, Australia
    Lipids 43:1031-8. 2008
    ..As RBC DHA was also negatively related to symptoms of depression, a randomised placebo-controlled study examining supplementation with LCn-3PUFA as an adjunct to standard pharmacotherapy appears warranted in this patient population...
  16. ncbi Manic symptoms in young males with ADHD predict functioning but not diagnosis after 6 years
    Philip L Hazell
    Center for Mental Health Studies, University of Newcastle, Newcastle, New South Wales, Australia
    J Am Acad Child Adolesc Psychiatry 42:552-60. 2003
    ..To compare the outcome in early adulthood of males who met criteria for attention-deficit/hyperactivity disorder (ADHD) and mania, ADHD alone, or no psychiatric disorder when aged 9-13 years...
  17. ncbi A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD
    Jan K Buitelaar
    Department of Psychiatry, University Medical Center Nijmegen, 9101, 6500, HB Nijmegen, The Netherlands
    Eur Child Adolesc Psychiatry 13:249-57. 2004
    ..CONCLUSION: These open-label data, gathered in an international setting, add to our knowledge of the value of atomoxetine in treating ADHD symptoms, as well as its safety and tolerability...
  18. ncbi Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder
    Mark E Bangs
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pediatrics 121:e314-20. 2008
    ..In this study we examined the effectiveness of atomoxetine for the treatment of oppositional defiant disorder comorbid with attention-deficit/hyperactivity disorder...
  19. ncbi What is a clinically important level of improvement in symptoms of attention-deficit/hyperactivity disorder?
    Philip Hazell
    Child and Youth Mental Health Service, Locked Bag 1014, Wallsend, NSW 2287, Australia
    Aust N Z J Psychiatry 39:354-8. 2005
    ....
  20. ncbi Comparison of diagnostic guidelines for juvenile bipolar disorder
    Catherine Cahill
    University of Sydney Discipline of Psychological Medicine, Royal North Shore Hospital, Sydney, Australia
    Aust N Z J Psychiatry 41:479-84. 2007
    ..It is recommended that clinicians and researchers need to develop diagnostic guidelines that have clinical salience and can be used for future research by incorporating key features of those that are currently available...
  21. ncbi Clinical management of deliberate self-harm in young people: the need for evidence-based approaches to reduce repetition
    Jane Burns
    beyondblue the national depression initiative Hawthorn West, Victoria, Australia
    Aust N Z J Psychiatry 39:121-8. 2005
    ..To examine the evidence for the effectiveness of clinical interventions designed to reduce the repetition of deliberate self-harm (DSH) in adolescents and young adults...